CG Oncology Inc. Common stock (CGON) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on CG Oncology Inc. Common stock (CGON) is Moderate Underperform.

The composite score behind that read is -0.27, weighing +0.11 of bullish evidence against -0.32 bearish.

CG Oncology Inc. Common stock last closed at $68.71, +1.97% on the session.

Against the IVW growth benchmark the position is +1.05% over the forecast window.

The read is built from 12 underlying insights — 1 bullish and 11 bearish.

Agreement across those insights is 92%.

9 graded predictions for CGON so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks CG Oncology Inc. Common stock in the 25th percentile on return on equity, where 100 is best.

CG Oncology Inc. Common stock is classified under Health Care / Biotechnology, with a market capitalisation of $5.97B.

StockMap tracks CG Oncology Inc. Common stock as the 43rd largest of the 344 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 180 Moderate Underperform, 152 Neutral, 11 Strong Underperform and 1 Moderate Outperform.

On that composite CG Oncology Inc. Common stock ranks 219th of 344 in the group, against a group median of -0.21.